Efficacy and tolerance of the topical application of potassium hydroxide (10% and 15%) in the treatment of molluscum contagiosum: Randomized clinical trial: Research protocol

BMC Infectious Diseases

Study Protocol

Helena Pera¹  Josep R Marsal²  Jordi Real²  Ines Cruz³  Gisela Galindo³  Olga Diez⁴  Concepcio Teixido⁴  Mireia Martinez⁵  Joan A Schoenenberger⁵ 

[1]Primary Care Research Institute IDIAP Jordi Gol, Catalan Institute of Health, Gran Via de les Corts Catalanes, 587, àticBarcelona, Spain

[2]Primary Care Research Institute IDIAP Jordi Gol, Catalan Institute of Health, Rambla de Ferran, 44, 3ª, Lleida, Spain

[3]Primary Care Research Institute IDIAP Jordi Gol, Catalan Institute of Health, Rambla de Ferran, 44, 3ª, Lleida, Spain

[4]Ronda Health Center, Catalan Institute of Health, C/de la Mercè, 5, Lleida, Spain

[5]Rambla de Ferran Health Center, Catalan Institute of Health, Rambla de Ferran, 44, Lleida, Spain

[6]University Hospital Arnau de Vilanova. Pharmacy Unit, Institut de Recerca Biomèdica de Lleida, Alcalde Rovira Roure, 80, Lleida, Spain

关键词: Atopic Dermatitis;    Isotretinoin;    Tretinoin;    Imiquimod;    Randomization Code;   

DOI  :  10.1186/1471-2334-11-278

 received in 2011-04-11, accepted in 2011-10-19,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundMolluscum contagiosum is a non-severe pediatric viral infection. Because it is highly contagious and current treatments have negative aesthetic and psychological effects, we want to test an alternative treatment in the primary care setting, consisting of two different concentrations of potassium hydroxide solution.Methods/designThe study design is a double-blind, randomized clinical trial, using three types of topical treatment. The treatment consist of daily applications of potassium hydroxide (KOH) in aqueous solution at 10% and 15% concentration, and a placebo administered in the control group. Four follow-up visits (at 15, 30, 45 and 60 days) are planned to evaluate treatment effectiveness and patient tolerance.The main outcome measure of the trial will be the healing rate, defined as lesion disappearance in the affected zones after the topic application of the experimental treatment. Secondary measures will be the principal characteristics and evolution of the affected zone (surface area, number of lesions, size and density of lesions), treatment tolerance (hyperpigmentation, itching, burning, pain), recurrence rate and the natural evolution of lesions in the control group.DiscussionKOH can potentially be an effective and safe treatment for MC in primary care, and can also reduce referrals to dermatologists and hospital pediatric departments. In addition, KOH may be a valid and less expensive alternative to current invasive treatments (surgical excision).Trial RegistrationClinicalTrials.gov: NCT01348386

【 授权许可】

Unknown   
© Marsal et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.